Priorix is a brand name vaccine that combines three live attenuated viruses: measles, mumps, and rubella (MMR). It is administered through injection and is primarily used to provide protection against these three contagious viral diseases.
Measles, also known as rubeola, is a highly contagious respiratory infection caused by the measles virus. Common symptoms of measles include fever, cough, runny nose, and a distinct rash that spreads all over the body. Mumps is an infectious disease caused by the mumps virus, characterized by fever, headache, and swelling of the salivary glands, particularly the parotid glands. Rubella, also known as German measles, is a viral infection that causes a red rash, low-grade fever, and swollen lymph nodes.
The Priorix vaccine contains weakened or attenuated versions of these viruses, stimulating the body's immune response without causing the full-blown diseases. By introducing weakened forms of these viruses, the vaccine prompts the immune system to produce antibodies that can combat future infections. This provides long-term immunity against measles, mumps, and rubella.
Priorix is commonly administered to infants, children, and adults as part of routine immunization programs. It is typically given as two doses, with the first dose recommended between 12 to 15 months of age and the second dose between 4 to 6 years of age. However, the vaccine may also be given to susceptible individuals who have not received the vaccine previously or have not had the diseases. It is safe and effective, playing a vital role in preventing the spread of measles, mumps, and rubella in populations.
